Introduction: Fetuin-A has been described to correlate inversely with vascular calcification both in animal models but also in patients with heart and renal disease. In this current study, we sought to investigate whether fetuin-A might be a useful marker for the discrimination of ischemic (ICM) from dilated cardiomyopathy (DCM).
Methods:
A total of 124 non-consecutive patients were included in this study, 59 patients suffered from ICM and 65 patients from DCM. Serum samples were obtained during out-patient visits and analyzed for fetuin-A by ELISA.
Results:
Median fetuin-A concentration in the overall cohort was significantly lower in ICM patients compared to DCM patients (62.2±16.4 μg/mL vs. 129.6±56.6 μg/mL;
P<.001).
A positive correlation of fetuin-A levels was found with BMI, cholesterol, LDL/HDL ratio and triglycerides and an inverse correlation with age (r=−.36; P<.001).
Moreover, patients suffering from (stable) angina pectoris evidenced lower fetuin-A levels compared to non-symptomatic patients (73.1±22.7 μg/mL vs. 83.7±26.2 μg/ mL; P=.047) Conclusions: Fetuin-A was shown to be a potential discriminator and biomarker for the differential diagnosis between ICM and DCM. Fetuin-A levels might also be helpful in the process of diagnostic decision-making in regards to invasive management or medical therapy.
K E Y W O R D S
biomarker, cardiomyopathy, ELISA, fetuin-A, heart failure scars might still be present in cardiac magnetic resonance imaging and coronary microcirculation might be impaired. 3, [7] [8] [9] Another important HF entity is dilated cardiomyopathy (DCM), which is considered to be the final common pathway of diverse genetic influences and environmental influences, mainly due to inflammation.
10,11
Fetuin-A is a glycoprotein mainly expressed and secreted from the liver and adipose tissue. 12 In 1944, fetuin has been described for the first time in fetal calf serum. 13 In the human setting, fetuin was initially named α2-Heremans-Schmid glycoprotein after its two discoverers. 14, 15 Fetuin-A is known to be increased in obesity, type 2 diabetes mellitus and metabolic syndrome. 16 On the other hand, fetuin-A is acting as an inhibitor of ectopic calcification and fetuin-A levels were reported to be inversely associated with calcification scores and both cardiovascular events and mortality. [17] [18] [19] Fetuin-A has been shown to influence a broad spectrum of cellular mechanisms both via direct interaction by preventing the formation of large crystals and also by regulating energy and bone metabolism. [20] [21] [22] [23] Moreover, fetuin-A has also been described as an inhibitor of vascular smooth muscle cell apoptosis. 24 It can also counteract effects of transforming growth factor-β and bone morphogenetic protein-2 on the formation of calcified tissue. 21, 25 So far, low serum fetuin-A levels were found in many pathological conditions with vascular calcifications such as coronary artery disease and degenerative valvular heart disease. [26] [27] [28] [29] We, therefore, investigated and compared fetuin-A levels in cardiomyopathies of differential pathogenesis, to evaluate fetuin-A as a potential biomarker for the discrimination of the etiology of ischemic cardiomyopathy (ICM) and DCM.
| METHODS

| Study population
One hundred and twenty-four, non-consecutive patients were in- (valvular heart disease, systemic disease involving the myocardium).
All patients suffered from HF with reduced ejection fraction. Serum samples were obtained from study patients after informed consent.
Aliquots of obtained serum samples were stored at −80°C until ELISA measurements were conducted. Patients suffering from active infection, malignant disease, or advanced renal failure (as indicated by a glomerular filtration rate <30 mL/min) were not included. The study was approved by the local ethics committee and conducted according to the Universal Declaration of Helsinki.
| Laboratory analysis
Laboratory parameters were measured by routine laboratory analysis. Fetuin-A concentration was determined by a commercially avail- 
| Statistical analysis
Statistical analysis was performed using SPSS (22.0; SPSS Inc., Armonk, NY, USA) and GraphPad-Prism software (GraphPad-Software, La Jolla, 
| RESULTS
Baseline characteristics are shown in There were no differences in medication, NYHA stadium or clinical symptoms such as angina and peripheral edema. (Table 2b ). In the DCM subgroup fetuin-A correlated positively with BNP and BMI (Table 2c ).
The median fetuin-A concentration in the overall cohort was 76.8±20.6 μg/mL and significantly higher in the DCM group compared to patients suffering from ICM (129.6±56.6 μg/mL vs. 62.2±16.4 μg/ mL; P<.001). As fetuin-A positively correlated with age and there was a significant age difference between those two groups, we also compared fetuin-A concentrations in those patients aged younger than 65 years (patient demographics see Table S1 ). Again, fetuin-A concentration in patients suffering from ICM was significantly lower compared to DCM patients (62.2±10.2 μg/mL vs. 153.4±58.7 μg/mL,
P<.001).
Except for creatinine levels and smoking status no significant differences were found between patients < or > 65 years of age. 
| DISCUSSION
Here, we demonstrate that fetuin-A concentrations differ between patients suffering from ICM and DCM, with patients suffering from
ICM showing lower levels. Fetuin-A might, therefore, constitute a valuable biomarker for the evaluation of etiology of cardiomyopathies.
In our overall cohort, fetuin-A negatively correlated with age.
As this correlation could not be shown in the distinct sub-cohorts, we think that this correlation is mainly due to the fact that patients suffering from ICM were older than those suffering from DCM and mainly driven by the different pathologies and etiologies underlying the cardiomyopathies. Although fetuin-A was reported to correlate with risk factors for coronary artery disease such as metabolic syndrome and obesity, lower fetuin-A levels in ICM patients corresponds to the finding of this protein being an inhibitor of ectopic calcification.
18
In the overall cohort but also in the ICM and DCM subgroups, fetuin-A positively correlated with BMI. As obesity and obesity-related diseases are known to be associated with cardiovascular diseases, this finding is somehow puzzling. Mathews et al. 30 have shown that fetuin knockout mice evidenced improved insulin sensitivity, lower blood glucose levels, and also a higher resistance against diet-induced obesity. Moreover, fetuin knockout mice demonstrated lower body weights compared to wild-type littermates. These in vivo animal data correspond nicely with the results obtained in our analysis of clinical data as a significant correlation with BMI (r=.34; P<.001) was found in our patient cohort. Moreover, patients with type 2 diabetes showed a trend toward higher fetuin-A concentrations (P=.1). 31, 32 We can only speculate that there might be an U-shaped relationship between fetuin-A and cardiovascular disease, with fetuin-A first being elevated due to sub-clinical inflammation 33, 34 T A B L E 2 (Continued)
